The pharmaceutical industry fears that the Biden patent movement will set a dangerous precedent
Profits in the pharmaceutical industry are backed by a patented fortress, which guarantees doctors an income until it expires. On Wednesday, Joe Biden broke with decades of U.S. orthodoxy and cracked a wall.
Of his administration decision The temporary waiver of the Covid-19 vaccine patent has sparked immediate outrage in the pharmaceutical sector, saying the move goes beyond intellectual property rights and will prevent U.S. innovation when jobs are sent abroad.
“Intellectual property is the lifeblood of biotechnology, it’s like oxygen to our industry,” said Brad Loncar, a biotechnology investor. “If you remove it, you don’t have a biotech sector.”
POLITICO
Get the Weekly Agriculture newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
With help from Ximena Bustillo
Editor’s Note: Weekly Agriculture is a weekly version of POLITICO Pro’s daily Agriculture policy newsletter, Morning Agriculture. POLITICO Pro is a policy intelligence platform that combines the news you need with tools you can use to take action on the day’s biggest stories. Act on the news with POLITICO Pro.